Zhu Z, Zhang J, Xu Z, Wang Q, Qi Y, Yang L
Int J Equity Health. 2025; 24(1):36.
PMID: 39905408
PMC: 11796270.
DOI: 10.1186/s12939-025-02390-w.
Ou P, Wen R, Shi L, Wang J, Liu C
Orphanet J Rare Dis. 2024; 19(1):345.
PMID: 39272071
PMC: 11401438.
DOI: 10.1186/s13023-024-03352-1.
Harlow E, Adair J
Nature. 2024; 631(8021):502-504.
PMID: 39020038
DOI: 10.1038/d41586-024-02310-y.
Pramesh C, Sengar M, Patankar S, Chinnaswamy G, Gupta S, Vijayakumar M
Bull World Health Organ. 2023; 101(9):587-594.
PMID: 37638358
PMC: 10452934.
DOI: 10.2471/BLT.23.289714.
Li M, Zhou N, Duan S, Zhong H, Jiang R, Yuan N
BMJ Open. 2023; 12(12):e066335.
PMID: 36600393
PMC: 9743400.
DOI: 10.1136/bmjopen-2022-066335.
A Cross-Sectional Study of Price and Affordability of Drugs for Rare Diseases in Shandong Province, China.
Mu Y, Song K, Song Y
Int J Environ Res Public Health. 2022; 19(20).
PMID: 36293897
PMC: 9602851.
DOI: 10.3390/ijerph192013319.
Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
Sun Y, Zhu Z, Zhang J, Han P, Qi Y, Wang X
Int J Environ Res Public Health. 2022; 19(8).
PMID: 35457445
PMC: 9025142.
DOI: 10.3390/ijerph19084578.
Sustainable Flow-Synthesis of (Bulky) Nucleoside Drugs by a Novel and Highly Stable Nucleoside Phosphorylase Immobilized on Reusable Supports.
Benitez-Mateos A, Paradisi F
ChemSusChem. 2021; 15(1):e202102030.
PMID: 34726353
PMC: 9298701.
DOI: 10.1002/cssc.202102030.
European collaborations on medicine and vaccine procurement.
Vogler S, Haasis M, van den Ham R, Humbert T, Garner S, Suleman F
Bull World Health Organ. 2021; 99(10):715-721.
PMID: 34621089
PMC: 8477421.
DOI: 10.2471/BLT.21.285761.
Biomedical Holistic Ontology for People with Rare Diseases.
Subirats L, Conesa J, Armayones M
Int J Environ Res Public Health. 2020; 17(17).
PMID: 32825147
PMC: 7503469.
DOI: 10.3390/ijerph17176038.
Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
Schey C, Postma M, Krabbe P, Topachevskyi O, Volovyk A, Connolly M
Front Public Health. 2020; 8:162.
PMID: 32457865
PMC: 7225315.
DOI: 10.3389/fpubh.2020.00162.
Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?.
Likic R
Br J Clin Pharmacol. 2020; 86(7):1233-1234.
PMID: 32291795
PMC: 7318998.
DOI: 10.1111/bcp.14295.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe C, Ferrario A
Front Public Health. 2018; 6:328.
PMID: 30568938
PMC: 6290038.
DOI: 10.3389/fpubh.2018.00328.
Mining Facebook Data of People with Rare Diseases: A Content-Based and Temporal Analysis.
Subirats L, Reguera N, Banon A, Gomez-Zuniga B, Minguillon J, Armayones M
Int J Environ Res Public Health. 2018; 15(9).
PMID: 30200209
PMC: 6163744.
DOI: 10.3390/ijerph15091877.
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
van der Gronde T, Uyl-de Groot C, Pieters T
PLoS One. 2017; 12(8):e0182613.
PMID: 28813502
PMC: 5559086.
DOI: 10.1371/journal.pone.0182613.
